AstraZeneca unveils new obesity drug
A recent study has shown that the anti-obesity drug Eliquoglifloron, from the "GLP-1" class, which is taken orally once daily, achieves significant weight loss and reduces appetite, with a safety profile comparable to other drugs in the same class. The study involved 310 participants and the results were published in "The Lancet" magazine, emphasizing the need for further large-scale clinical trials to confirm its long-term efficacy and safety, with the goal of pursuing marketing authorization.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)